Results 11 to 20 of about 5,151 (200)

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose. [PDF]

Hemodial Int
ABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Jardine A, Burke SK, Luo W, Minga T, Sarnak MJ, Winkelmayer WC, Agarwal R, Chertow GM, Eckardt KU, Koury MJ.   +9 more
europepmc   +2 more sources

Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real-World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study. [PDF]

Nephrology (Carlton)
The study investigated the association between darbepoetin alfa (DA) dosage and urinary protein levels in real‐world chronic kidney disease (CKD) patients. High‐dose DA administration was associated with reduced proteinuria, particularly in diabetic kidney disease (DKD) patients with high erythropoiesis resistance index (ERI‐1B) values, suggesting ...
Hirashio S, Masaki T, Kagimura T, Narita I.   +3 more
europepmc   +2 more sources

Hepatic modulation of apelin and galectin-3 by darbepoetin-alpha in Dexamethasone induced insulin-resistant rats [PDF]

BMC Pharmacology and Toxicology
Background Insulin resistance (IR) is a central pathological mechanism underlying metabolic syndrome and associated disorders, including type 2 diabetes and non-alcoholic fatty liver disease. This study investigated the therapeutic effects of darbepoetin
Halime Tozak Yildiz, Ahmet Turk, Ertan Katirci, Kubra Tugce Kalkan   +3 more
doaj   +2 more sources

Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data

Turkish Journal of Hematology, 2023
Objective: This study was undertaken to evaluate the long-term clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndrome (MDS) in a real-life setting. Materials and Methods: A total of 204 patients with low-risk or
Müzeyyen Aslaner Ak, Ayfer Gedük, İbrahim Halil Açar, Merve Gökçen Polat, Cenk Sunu, Ali Zahit Bolaman, Tuba Hacıbekiroğlu, Birol Güvenç, Şehmus Ertop   +8 more
doaj   +1 more source

THE CLINICAL EFFICACY OF EPOETIN ALFA AND DARBEPOETIN ALFA IN PATIENTS WITH LOW-RISK OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROME: RETROSPECTIVE MULTI-CENTER REAL-LIFE STUDY

Hematology, Transfusion and Cell Therapy, 2023
Objective: This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting.
Müzeyyen Aslaner Ak, Birsen Sahip, Ayfer Geduk, Mehmet Ali Uçar, Hacer Kale, Tugba Hacibekiroglu, Merve Gokcen Polat, Yasin Kalpakcı, Ali Zahit Bolaman, Birol Guvenc, Sehmus Ertop   +10 more
doaj   +1 more source

Darbepoetin Alfa (Aranesp) [PDF]

Baylor University Medical Center Proceedings, 2002
The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia in patients ...
John, Powell, Cheryle, Gurk-Turner
openaire   +2 more sources

COST-MINIMIZATION ANALYSIS OF USING SHORT AND LONG-ACTING ERYTHROPOESIS-STIMULATING AGENTS FOR CORRECTION OF NEPHROGENIC ANEMIA AGAINST THE BACKGROUND OF SUBSTITUTION THERAPY

Фармация и фармакология (Пятигорск), 2021
Clinical trials conducted in various countries indicate that the use of epoetin alfa in patients with nephrogenic anemia in chronic kidney disease can increase the effectiveness of treatment, reduce the incidence of cardiovascular and infectious ...
I. S. Krysanov, E. Yu. Ermakova, L. B. Vaskova, M. V. Tiapkina   +3 more
doaj   +1 more source

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study [PDF]

, 2018
Aims: To test the prognostic value of emerging biomarkers in the Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial. Methods and results: Circulating cardiac [N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high ...
Alehagen, Arimoto, Balling, Bolignano, Cabassi, Dupont, Gaggin, Gravning, Grodin, Guisado Espartero, Haehling, Harrell, Jackson, Lassus, Lassus, Lok, Maisel, Maisel, McMurray, McMurray, Miller, Miller, Nagarajan, Park, Pascual-Figal, Pencina, Pencina, Pocock, Ponikowski, Rahimi, Rush, Shlipak, Swedberg, Tentzeris, Zamora   +34 more
core   +9 more sources

Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes [PDF]

Journal of Nephropharmacology, 2020
Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating ...
Tarun Kumar Jeloka, Datta Jayanta, Suresh Babu Vallamkonda, Sujeet Narayan Charugulla, Gupta Namita   +4 more
doaj   +1 more source

USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP [PDF]

Journal of IMAB, 2017
Darbepoetin alfa (DA) is indicated for treatment of symptomatic anemia related to chronic kidney disease (CKD) in adult and pediatric patients. In comparison with the recombinant human erythropoietin (rHuEpo), darbepoetin alfa has two additional ...
Maria Gaydarova, Anelia Boueva, Svetlana Marinova, Galina Zlatanova   +3 more
doaj   +1 more source